Yes. Well, they've been making a lot of changes as well. Again, we're not saying that progressive licensing is fast-tracking; rather, progressive licensing describes the way we generally market-authorize a drug, and there's no reduction in standards here.
We're adding to the post-market, because you can only know so much when you first authorize a drug, and then when it moves out into the community of use, you can start to see things that you wouldn't see in a clinical trial. We want to make sure we have really good tools that are very enforceable and effective in communicating, because it's not just enforcement that matters, but also that we're actually communicating well with health care professionals and the consumers and patients who are taking a drug.